Möchten Sie immer auf dem neuesten Stand bleiben?

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 30, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2025. Business highlights Q1...

Daridorexant improved sleep maintenance throughout the entire night, including the last quarter, while also improving next-morning sleepiness.Daridorexant improved next-morning sleepiness compared to...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – April 16, 2025Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere...

Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria in Black patients with confirmed resistant hypertension...

Allschwil, Switzerland – April 9, 2025Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business...

Ad hoc announcement pursuant to Art. 53 LR FDA confirms that prescribers and pharmacists are no longer expected to interact with the REMS Allschwil, Switzerland – March 17, 2025Idorsia Ltd (SIX:...

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024. Business highlights 2024 Viatris...

Ad hoc announcement pursuant to Art. 53 LR More than the required two-thirds majority of bondholders reach agreement on the main terms for the restructuring of Idorsia’s outstanding convertible bond...